Accipiter Biosciences Secures $12.7M Seed Funding, Revolutionizing Protein Therapies
November 8, 2025, 3:55 pm
Location: United States, Washington, Seattle
Employees: 1-10
Founded date: 2016
Columbus Venture Partners
Employees: 11-50
Accipiter Biosciences, a Seattle biotech, exited stealth with $12.7 million in seed funding. The company pioneers de novo multifunctional protein therapeutics. Its computational platform designs novel biologics from scratch. These single molecules target complex diseases. They activate multiple biological pathways simultaneously. This approach promises more precise and effective treatments. It aims to replace cumbersome drug combinations. Strategic collaborations with Pfizer and Kite Pharma boost its pipeline. Accipiter focuses on immunology and oncology programs. This represents a significant leap in advanced drug development.
Seattle’s biotechnology sector expands its innovative frontier. Accipiter Biosciences recently emerged from stealth. The company announced a substantial $12.7 million in seed funding. This investment propels a new generation of de novo multifunctional protein therapeutics. These advanced biologics aim to treat complex diseases.
The seed round saw robust participation. Takeda and Flying Fish Partners co-led the financing. Additional investors included Columbus Venture Partners, Cercano Capital, Washington Research Foundation, Alexandria Investments, Pack Ventures, and Argonautic Ventures. This diverse support underscores confidence in Accipiter’s vision. The capital influx will accelerate its ambitious plans.
Accipiter Biosciences focuses on creating entirely new biologic therapies. These are built from scratch. They do not modify existing natural proteins. This radical approach defines "de novo" protein design. It opens vast therapeutic possibilities. The company leverages a powerful computational technology platform. This platform integrates with high-throughput experimentation. Together, they design proteins. These proteins activate multiple biological pathways. Simultaneous activation is a key feature.
Complex diseases often require multi-pathway intervention. Current solutions typically involve drug combinations. These combinations carry significant drawbacks. Development costs are high. Clinical trials are time-consuming and expensive. They also increase the risk of side effects. Individual drugs may not work together optimally. They might move through the body differently. This hinders their combined effect. Accipiter’s innovative biologics address these challenges directly. They combine numerous therapeutic mechanisms. A single therapeutic molecule delivers this integrated action. This promises superior precision and efficacy. It simplifies treatment regimens.
The company’s platform enables rapid iteration. Design-to-lab timelines are remarkably short. They often fall under two months. This speed is critical in drug development. It accelerates the discovery process. It brings potential therapies to patients faster. These multifunctional biologics are custom-built. They are designed using proprietary computational methods. Each molecule combines multiple mechanisms. This creates a stable, integrated therapeutic agent. It applies to any therapeutic application.
Accipiter Bio’s biologics offer unique advantages over traditional treatments. Many antibodies and multispecifics primarily block cellular pathways. Accipiter’s molecules include agonists. Agonists precisely and specifically activate multiple pathways. This happens on the same cell, simultaneously. This approach leverages biological synergy. It enhances therapeutic outcomes.
Funds from the seed financing fuel several strategic initiatives. Accipiter will expand its internal pipeline. Initial focus areas include immunology and oncology. The company plans to advance up to two programs. These will move towards pre-IND (Investigational New Drug) status. Furthermore, it will continue enhancing its proprietary computational capabilities. Continuous platform development is essential for sustained innovation.
The founding team brings extensive expertise. Their backgrounds include significant contributions to de novo protein design. Members hail from prominent institutions. These include Seagen, Merck, Neoleukin Therapeutics, and the University of Washington’s Institute for Protein Design. This team previously contributed to a landmark achievement. They helped develop the first fully de novo protein therapeutic. That molecule reached clinical trials. This experience provides a strong foundation.
Accipiter’s leadership includes seasoned professionals. Dr. Matthew Bick is co-founder and Chief Executive Officer. Dr. Javier Castellanos serves as co-founder and Chief Technology Officer. Dr. Hector Rincon is co-founder and Chief Scientific Officer. Dr. William Canestaro holds roles as Chief Operating Officer and Chief Strategy Officer. This executive team guides the company's strategic direction.
Beyond its internal pipeline, Accipiter Biosciences forged key alliances. Strategic research collaborations exist with Pfizer and Kite Pharma. Kite Pharma is a Gilead company. These partnerships underscore the platform’s broad potential.
The agreement with Pfizer is significant. Accipiter is eligible for an upfront payment. Further development and commercial milestones could total over $330 million. Royalties are also part of the deal. This collaboration focuses on discovering and designing new biologics. It targets multiple therapeutic areas. This partnership validates Accipiter’s technology. It provides substantial resources for future endeavors.
The partnership with Kite Pharma establishes a multi-target collaboration. This alliance focuses on generating molecules specifically for cell therapies. It includes potential milestone payments and royalties. These payments tie to development success and commercial outcomes. Integrating Accipiter’s novel biologics into cell therapies could unlock new treatment modalities. It could enhance existing cellular approaches.
Accipiter Biosciences envisions a future of medicine. This future features more precise and effective treatments. These treatments target complex diseases. Such conditions often demand intervention across multiple biological pathways. The seed financing and strategic partnerships are crucial. They accelerate the advancement of Accipiter’s platform. They also push its therapeutic programs toward clinical evaluation. The company aims to deliver better, more convenient care to patients globally. This innovative biotechnology firm stands poised to reshape drug development. Its impact on immunology and oncology could be profound.
Seattle’s biotechnology sector expands its innovative frontier. Accipiter Biosciences recently emerged from stealth. The company announced a substantial $12.7 million in seed funding. This investment propels a new generation of de novo multifunctional protein therapeutics. These advanced biologics aim to treat complex diseases.
The seed round saw robust participation. Takeda and Flying Fish Partners co-led the financing. Additional investors included Columbus Venture Partners, Cercano Capital, Washington Research Foundation, Alexandria Investments, Pack Ventures, and Argonautic Ventures. This diverse support underscores confidence in Accipiter’s vision. The capital influx will accelerate its ambitious plans.
Accipiter Biosciences focuses on creating entirely new biologic therapies. These are built from scratch. They do not modify existing natural proteins. This radical approach defines "de novo" protein design. It opens vast therapeutic possibilities. The company leverages a powerful computational technology platform. This platform integrates with high-throughput experimentation. Together, they design proteins. These proteins activate multiple biological pathways. Simultaneous activation is a key feature.
Complex diseases often require multi-pathway intervention. Current solutions typically involve drug combinations. These combinations carry significant drawbacks. Development costs are high. Clinical trials are time-consuming and expensive. They also increase the risk of side effects. Individual drugs may not work together optimally. They might move through the body differently. This hinders their combined effect. Accipiter’s innovative biologics address these challenges directly. They combine numerous therapeutic mechanisms. A single therapeutic molecule delivers this integrated action. This promises superior precision and efficacy. It simplifies treatment regimens.
The company’s platform enables rapid iteration. Design-to-lab timelines are remarkably short. They often fall under two months. This speed is critical in drug development. It accelerates the discovery process. It brings potential therapies to patients faster. These multifunctional biologics are custom-built. They are designed using proprietary computational methods. Each molecule combines multiple mechanisms. This creates a stable, integrated therapeutic agent. It applies to any therapeutic application.
Accipiter Bio’s biologics offer unique advantages over traditional treatments. Many antibodies and multispecifics primarily block cellular pathways. Accipiter’s molecules include agonists. Agonists precisely and specifically activate multiple pathways. This happens on the same cell, simultaneously. This approach leverages biological synergy. It enhances therapeutic outcomes.
Funds from the seed financing fuel several strategic initiatives. Accipiter will expand its internal pipeline. Initial focus areas include immunology and oncology. The company plans to advance up to two programs. These will move towards pre-IND (Investigational New Drug) status. Furthermore, it will continue enhancing its proprietary computational capabilities. Continuous platform development is essential for sustained innovation.
The founding team brings extensive expertise. Their backgrounds include significant contributions to de novo protein design. Members hail from prominent institutions. These include Seagen, Merck, Neoleukin Therapeutics, and the University of Washington’s Institute for Protein Design. This team previously contributed to a landmark achievement. They helped develop the first fully de novo protein therapeutic. That molecule reached clinical trials. This experience provides a strong foundation.
Accipiter’s leadership includes seasoned professionals. Dr. Matthew Bick is co-founder and Chief Executive Officer. Dr. Javier Castellanos serves as co-founder and Chief Technology Officer. Dr. Hector Rincon is co-founder and Chief Scientific Officer. Dr. William Canestaro holds roles as Chief Operating Officer and Chief Strategy Officer. This executive team guides the company's strategic direction.
Beyond its internal pipeline, Accipiter Biosciences forged key alliances. Strategic research collaborations exist with Pfizer and Kite Pharma. Kite Pharma is a Gilead company. These partnerships underscore the platform’s broad potential.
The agreement with Pfizer is significant. Accipiter is eligible for an upfront payment. Further development and commercial milestones could total over $330 million. Royalties are also part of the deal. This collaboration focuses on discovering and designing new biologics. It targets multiple therapeutic areas. This partnership validates Accipiter’s technology. It provides substantial resources for future endeavors.
The partnership with Kite Pharma establishes a multi-target collaboration. This alliance focuses on generating molecules specifically for cell therapies. It includes potential milestone payments and royalties. These payments tie to development success and commercial outcomes. Integrating Accipiter’s novel biologics into cell therapies could unlock new treatment modalities. It could enhance existing cellular approaches.
Accipiter Biosciences envisions a future of medicine. This future features more precise and effective treatments. These treatments target complex diseases. Such conditions often demand intervention across multiple biological pathways. The seed financing and strategic partnerships are crucial. They accelerate the advancement of Accipiter’s platform. They also push its therapeutic programs toward clinical evaluation. The company aims to deliver better, more convenient care to patients globally. This innovative biotechnology firm stands poised to reshape drug development. Its impact on immunology and oncology could be profound.